Xia Xu

发表

Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial

J. Gatell, H. Teppler, F. Raffi, 2019, Antiviral therapy.

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

J. Gatell, H. Teppler, Charlotte M. Harvey, 2014, Journal of the International AIDS Society.

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

P. Sax, K. Squires, P. Cahn, 2018, Journal of acquired immune deficiency syndromes.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A. Lazzarin, M. Saag, J. Rockstroh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

S. Spector, H. Teppler, E. Acosta, 2015, Journal of the Pediatric Infectious Diseases Society.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

S. Spector, H. Teppler, E. Acosta, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-Term Safety from the Raltegravir Clinical Development Program

R. Leavitt, H. Teppler, F. Lievano, 2011, Current HIV research.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Adriano Lazzarin, Edwin DeJesus, Peter Sklar, 2009, The Lancet.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

C. Katlama, P. Sax, Y. Yazdanpanah, 2017, The lancet. HIV.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, C. Orkin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

P. Sax, K. Squires, P. Cahn, 2018, The lancet. HIV.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

D. Cooper, M. Youle, R. Leavitt, 2010, The Lancet.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein.

N. Abate, C. Ballantyne, A. Catapano, 2008, Journal of clinical lipidology.

Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.

A. Dicker, Y. Lawrence, B. Daróczi, 2012, International journal of radiation oncology, biology, physics.

Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.

P. Sax, K. Squires, P. Cahn, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

A. Lazzarin, R. Leavitt, R. Pollard, 2009, The Lancet.

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

P. Sax, J. Gatell, K. Squires, 2018, Open Forum Infectious Diseases.

Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.

A. Lazzarin, M. Saag, J. Rockstroh, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.